Data updated: Mar 29, 2026

HETERO LABS LTD VI

Oncology

Generics

HETERO LABS LTD VI is a generic drug manufacturer focused on Oncology.

2024

Since

6

Drugs

-

Trials

44

Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues ProEarly access

Loading...

Revenue Over Time ProEarly access

Loading...

Recent Activity

OXALIPLATIN 2026-01-15

BORTEZOMIB 2026-01-06

DECITABINE 2025-12-19

BORTEZOMIB 2025-12-17

PEMETREXED DISODIUM 2025-12-15

OXALIPLATIN 2025-10-22

PEMETREXED DISODIUM 2025-10-09

PEMETREXED DISODIUM 2025-08-06

SEC Filings ProEarly access

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 100%

4 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones ProEarly access

Loading...

Patent Cliff ProEarly access

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma

Novartis big-pharma

Merck big-pharma

Baxter specialty

AbbVie big-pharma